QuidelOrtho Reports Second Quarter 2026 Financial Results

QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 QuidelOrtho Reports Second Quarter 2026 Financial Results ― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth― ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company upda

Event · Guidance
Metric
Total revenues (reported)
Period
Full-year 2026
New
$2.52 - $2.60 billion
Prior
$2.70 - $2.75 billion
Direction
lower

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 6, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$QDEL
Bearish
high confidence
Mentioned
$QDEL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QDELBearishHigh
01

Why it matters

The key tradable items are the updated revenue, adjusted EBITDA, and adjusted EPS ranges, plus the explicit withdrawal of free cash flow guidance. The company links the reset to China demand headwinds from proposed IVD pricing changes and a softer global respiratory environment, while noting ex-China growth strength.

02

Market read

Traders can update valuation and positioning based on the guidance cut and the new cash-conversion uncertainty signaled by the FCF withdrawal.

03

What to watch

The company attributes China weakness to proposed IVD pricing guideline changes and also withdraws FCF guidance due to working-capital impacts, so investors should separate demand softness from cash timing effects.

Relevance 7/10Novelty 9/10Timing: after-hours guidance update filed today (Aug 6, 2026)

Background

This is QuidelOrtho’s SEC Form 8-K reporting Q2 2026 results and updated full-year 2026 financial guidance, including a decision to withdraw free cash flow guidance.

Company-level read

Ticker impact

$QDELBearishHigh confidence
Context

QuidelOrtho reported Q2 revenue of $631M and revised full-year 2026 guidance, including withdrawing free cash flow guidance amid China headwinds.

Expected impact

Near-term volatility likely as investors reprice 2026 revenue and EBITDA expectations and focus on working-capital driven cash uncertainty.

Evidence & confidence

The filing discloses specific updated ranges for total revenue, adjusted EBITDA, adjusted EPS, and explicitly withdraws free cash flow guidance, tied to China demand headwinds and working-capital impacts.

Market effects

Diagnostic/IVD peers may see read-across on China pricing pressure and respiratory demand softness, but the impact is company-specific.

China weakness is explicitly cited as a driver of the guidance reset, highlighting regional demand sensitivity.

Limited broader macro relevance; primarily a single-company earnings and cash-conversion signal.

Counterpoint

Ex-China revenue growth (Labs +9%, Immunohematology +5%) and improved adjusted EBITDA margin could support a faster-than-expected normalization if China stabilizes.

Key entities

  • QuidelOrtho Corporation

    Nasdaq-listed diagnostics provider reporting Q2 results and updating 2026 guidance, citing China headwinds and withdrawing free cash flow guidance.

  • Brian J. Blaser

    CEO who commented on Q2 performance, China demand headwinds, and the guidance revisions.

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.